THERAPY TO PREVENT HEPATOCELLULAR CARCINOMA IN PEOPLE WITH LIVER CIRRHOSIS
Professor John Olynyk, Liver Specialist, Gastroenterologist & Hepatologist,
Fiona Stanley and Fremantle Hospitals
South Metropolitan Health Service, Western Australia &
Associate Director, Clinical Engagement,
Curtin Medical Research Institute, Curtin University, Western Australia
RESEARCHER PROFILE
Filmed in Perth, Western Australia | February 2026
Professor John Olynyk is a Gastroenterologist & Hepatologist with over 30 years’ experience, primarily at The Fiona Stanley & Fremantle Hospital Group. He planned the Gastroenterology and Hepatology Service for the Fiona Stanley Hospital and was Head Department from 2010 until 2020.
Professor John Olynyk was appointed as Associate Dean and Head of the Medical Discipline at Curtin University in 2023 until 2025 and is now Associate Director, Clinical Engagement, Curtin Medical Research Institute, Curtin University.
Professor John Olynyk has a long and productive history of research in the field of haemochromatosis, liver disease and iron metabolism. He has sustained 27 years of continuous funding from the NHMRC and published over 270 peer reviewed publications with nearly 20,000 citations. He is patron of Haemochromatosis Australia and currently serves on the Royal Australasian College of Physicians overseas trained physicians assessment panel.
He has been a member of multiple national and international professional organisations. He was a keynote speaker at the UK Liver Cancer Meeting at Cambridge University in 2024. Currently he is leading a multicentre, international NHMRC-funded clinical trial examining whether aspirin therapy can prevent hepatocellular carcinoma in people with cirrhosis.
Source: Supplied
https://orcid.org/0000-0003-0417-3411
-
Causal genes and pathogenic mechanisms underlying gastrointestinal diseases
Professor D’Amato has more than 25 years research experience in the field of human genetics and complex diseases, with activities most recently geared towards a translational application for therapeutic precision in gastroenterology. His team, the Gastrointestinal Genetics Laboratory, combine leading expertise in genomic, computational and pre-clinical research, and have contributed important breakthroughs linking specific genes and pathogenetic mechanisms to a number of gastrointestinal diseases like inflammatory bowel disease (IBD), microscopic colitis (MC) and irritable bowel syndrome (IBS).
-
Nuclear medicine & theranostics for molecular imaging & targeted therapy
Dr Aviral Singh is a globally renowned Nuclear Medicine Physician with special interest in Theranostics.
Dr Singh is based in Perth, Western Australia since 2024 and serves as the Clinical Head of Theranostics and Nuclear Medicine at GenesisCare Australia. He is also a Consultant Nuclear Medicine Physician at Fiona Stanley and Royal Perth Hospitals, in addition to pursuing national and international consulting physician roles as Director at Infinity Theranostics.
-
Vision impairment in children and the impact on children and their families
Dr Sue Silveira holds a conjoint academic position with Macquarie University and is the Course Director for their Master of Disability Studies, which is administered and delivered by NextSense Institute in affiliation with the University. She teaches in the areas of vision impairment and disability, and aims to share her knowledge while learning from others, especially people who are blind or have low vision and their families.
